. 2015 Jul 21;21(27):8271–8283. doi: 10.3748/wjg.v21.i27.8271

Table 6.

Lung or thoracic cancer studies n (%)

Author	Type of microsphere	Type of mets (patients)	Response criteria	Response	Median OS
(publish date and study type)	(average dosage or activity)	Type of mets (patients)	@ 1^st assessment	Response	Median OS
Gaba et al[36]	Therasphere	Squamous cell lung cancer (2)	PET CT	2 (100) CR	Patient 1: Alive 11 mo after SIRT
(8/2012, case report)	(1.57-3 Gbq)	Squamous cell lung cancer (2)	@ 2-3 mo	2 (100) CR	Patient 2: Alive 2 mo after SIRT
Murthy et al[44]	SIR-Spheres	Lung cancer (6)	Unspecified	1 (17) PR	2.7 mo
(2/2008, RS)	(no dosage info)	2 carcinoids 3 adenocarcinomas	@ unspecified	1 (17) “minor response”
		1 small cell carcinoma		1 (17) SD
				3 (50) PD
Reiner et al[46]	SIR-Spheres	NSCLC (1, data extracted from larger study)	RECIST 1.1	1 (100) CR/PR	None
(1/2014, PC)	(mean 1.5 Gbq)	NSCLC (1, data extracted from larger study)	@ 4 mo	1 (100) CR/PR	None

SIRT: Selective internal radiation therapy; RS: Retrospective study; PC: Prospective cohort study; CR: Complete response; PR: Progressive response; PD: Progressive disease; SD: Stable disease; OS: Overall survival.